CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 87 target
Drug / intervention
Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone +6 moredrug
Likely dose
Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone 800mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07168980
NCT07168980Phase 2RecruitingOn Track
CompareCT.gov

Intensive Chemotherapy Combined With Early, Adequate, and Intensive Use of Rituximab for Aggressive B-NHL in Children and Adolescents

Children's Cancer Group, China·interventional·Posted Sep 11, 2025·Updated Jun 4, 2026

In Brief

A Phase 2 clinical trial evaluating Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone, and 4 other interventions for Mature B-cell Non-Hodgkin Lymphoma. Currently recruiting, targeting 87 participants across 1 site.

Detailed Summary

The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMature B-cell Non-Hodgkin Lymphoma
CountriesChina
CollaboratorsShanghai Children's Medical Center, Nanjing Children's Hospital, Children's Hospital of Soochow University, West China Second University Hospital, Qilu Hospital of Shandong University, Tianjin Medical University Cancer Institute and Hospital, Xiangya Hospital of Central South University, Wuhan TongJi Hospital

Timeline

Phase 2Recruiting
20262027202820292030
First PostedSep 11, 2025
Enrollment StartJul 1, 2025
Primary CompletionJun 30, 2030
TodayJul 1, 2026
Enrollment to primary: 5.0 yearsPosted 10 months agoPrimary completion in 4.0 years

Arms & Interventions

Risk group 1other

Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);

Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, PrednisoneDrug: Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
Risk group 2other

Not or incompletely resected stage I/II disease and LDH \<2ULN: 5 courses (A--B--A--B--A) and 8 intrathecal injections;

Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, PrednisoneDrug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone
Risk group 3other

Stage III with LDH \< 2 ULN, or Stage I,II with LDH in 2 to 4 ULN : Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-AA-BB-AA-BB-AA-BB) and 13 intrathecal injections(16 intrathecal injections with CNS2-3)

Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, PrednisoneDrug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, PrednisoneDrug: Prednisone,Vincristine, Cyclophosphamide
Risk group 4other

Stage III with LDH≥2ULN, or Stage IV, or B-AL: Preface followed by 6 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections((16 intrathecal injections with CNS2-3): P-(Rituximab-Rituximab)AA-(Rituximab-Rituximab)BB-(Rituximab)AA-(Rituximab)BB-AA-BB; stage IV or B-AL with LDH≥5ULN:P-(Rituximab-Rituximab)AA-(Rituximab-Rituximab)BB-(Rituximab)AA-(Rituximab)BB-AA-BB-AA-BB, together with 17 intrathecal injections((21 intrathecal injections with CNS2-3)

Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, PrednisoneDrug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, PrednisoneDrug: Prednisone,Vincristine, Cyclophosphamide

Interventions

Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisonedrug

Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;

Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisonedrug

Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;

Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisonedrug

Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisonedrug

Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1

Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisonedrug

Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4; Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4; Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,4(CNS2-3),8

Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisonedrug

Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8

Prednisone,Vincristine, Cyclophosphamidedrug

Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1